Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma

Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update

(2021) Masatoshi Kudo et al.   Liver Cancer

Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib

(2021) Toshifumi Tada et al.   Scientific Reports

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study

(2021) Atsushi Hiraoka et al.   Scientific Reports

Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade

(2020) Takashi Kumada et al.   Liver Cancer

Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib

(2020) Yuwa Ando et al.   ONCOLOGY

Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study

(2019) Kazuomi Ueshima et al.   Cancers

Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma

(2019) Atsushi Hiraoka et al.   ONCOLOGY

Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis

(2018) Atsushi Hiraoka et al.   Liver Cancer

Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm

(2017) Masatoshi Kudo   Liver Cancer

Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications

(2017) Atsushi Hiraoka et al.   Liver Cancer

Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade

(2015) Philip J. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY